With every new discovery, our platform gets smarter, and our pipeline grows.

Phase 1

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

Solid Tumors

Preclinical

Dilated Cardiomyopathy

Clostridium difficile Colitis

Neuroinflammation

Batten Disease

Charcot-Marie-Tooth Disease

Pulmonary Arterial Hypertension

Discovery

Lung Disease

Senescence

Vascular Disease

Oncology 1

Oncology 2

Early Discovery

+ 18 early
discovery programs

Phase 2
Phase 3
Commercial
Disease Model
Early Discovery
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

Solid Tumors

Dilated Cardiomyopathy

Clostridium difficile Colitis

Neuroinflammation

Batten Disease

Charcot-Marie-Tooth Disease

Pulmonary Arterial Hypertension

Lung Disease

Senescence

Vascular Disease

+ 18 early
discovery programs

Oncology 1

Oncology 2

Phase 1

Neurofibromatosis Type 2

Cerebral Cavernous Malformation

GM2 Gangliosidosis

*Undisclosed indication

Disease Model
Early Discovery
Discovery
Preclinical
Phase 1
Phase 2
Phase 3
Commercial
Neurofibromatosis Type 2
Cerebral Cavernous Malformation
GM2 Gangliosidosis
Solid Tumors
Dilated Cardiomyopathy
Clostridium difficile Colitis
Neuroinflammation
Batten Disease
Charcot-Marie-Tooth Disease
Pulmonary Arterial Hypertension
Lung Disease
Senescence
Vascular Disease
Oncology 1
Oncology 2
18

Early Discovery

Metabolic Disorders
Tumor Suppression
Cancers
Mitochondrial Diseases
Lysosomal Storage Disorders
Nervous System Disorders
Neurodevelopment Disorders
Neurodegenerative Disorders
Inflammation

4

Discovery

Lung Disease
Senescence
Vascular Dysplasia
Tumor Suppression

6

Preclinical

Dialated Cardiomyophathy
Clostridium Difficile Colitis
Amitrophic Lateral Sclerosis
Batten Disease
Charcot-Marie-Tooth Disease
Pulmonary Arterial Hypertension

3

Phase 1

Neurofibromatosis Type 2
Cerebral Cavernous Malformation
*Undisclosed indication

More on our lead, clinical-stage programs:

Rec-994 for Cerebral Cavernous Malformation

Cerebral cavernous malformation (CCM) is a rare, genetic disease that affects up to 1.5 million people in the U.S. CCM is defined as a collection of small blood vessels in the brain — malformations — that are enlarged and irregular and can lead to altered blood flow.

REC-994 is Recursion’s first clinical program, discovered using a basic machine learning system that was the seed for Recursion’s drug discovery platform. REC-994 is a well-characterized, small molecule that has been granted Orphan Drug Designation by the U.S. FDA for the potential treatment of symptomatic CCM and by the European Medicines Agency for the potential treatment of familial CCM.

Recursion has successfully completed Phase 1 studies, and the team is currently preparing REC-994 for Phase 2 clinical trials.

Rec-2282 for Neurofibromatosis
type 2 (NF2)

Neurofibromatosis type 2 (NF2) is a rare, genetic disease most commonly associated with benign, non-cancerous tumours that occur on the nerves responsible for balance and hearing in the inner ear (known as acoustic neuromas). It’s estimated that 1 in 33,000 people worldwide are affected by NF2. Mutations in the NF2 gene also drive other oncology conditions.

REC-2282 was discovered on Recursion’s platform after a search for potential therapies for NF2 revealed the clinical candidate among shelved compounds with the promise for accelerated development. Recursion in-licensed the compound from Ohio State University to be developed for NF2.

Our first wholly owned subsidiary company, CereXis, Inc., is currently preparing REC-2282 for Phase 2 clinical trials. For more information, please visit their website.


Welcome to the era of industrialized drug discovery